RxDoctor Payments Data

Jeffrey Ogbara, MD

Internal Medicine · Philadelphia, PANPI 1528112513

Payments from drug & device makers

$28,790in general payments, 2019–2025

Across 426 payments — averaging $67.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Abbott$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Teleflex LLC$2K
  • Penumbra, Inc.$1K
  • Stryker$671
  • plus $4K from 30 others
$1,350in research payments, 2019–2025

Across 1 payment — averaging $1350.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1K

What the payments were for

  • Consulting fees$5002%
  • Speaking & faculty fees$1,5005%
  • Grants$550%
  • Travel & lodging$10,16135%
  • Food & beverage$16,57458%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,790 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$276,449
Medicare patients
925
Services billed
2,944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$136,879
EntrestoSacubitril/Valsartan96$124,212
BrilintaTicagrelor29$32,253
FarxigaDapagliflozin Propanediol31$28,203
XareltoRivaroxaban21$26,258
JardianceEmpagliflozin13$16,115
Metoprolol Succinate239$3,564
Atorvastatin Calcium203$3,067
Carvedilol154$1,866
ClopidogrelClopidogrel Bisulfate86$1,307
Valsartan50$1,140
Bumetanide27$914
Rosuvastatin Calcium38$718
Furosemide122$631
Losartan Potassium72$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$186$136,879112 claims
NovartisEntresto$436$124,21296 claims
AstraZenecaBrilinta, Farxiga$282$60,45660 claims
Johnson & JohnsonXarelto$429$26,25821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →